Replies to post #251814 on Biotech Values

[oc631]

What if Nuvaxovid isn't approved in the U.S. by the 2025/2026 season? If you have followed NVAX in the past don't say this can't happen.

Filip Dubovsky head of R&D at NVAX to retire. The only person with redeemable value at this organization IMO.


https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318344316&type=HTML&symbol=NVAX&cdn=c539b5e2b1680d82aeda2a9a50c04b46&companyName=Novavax+Inc.&formType=8-K&dateFiled=2024-05-23